(Q34725589)

4 August 2017

title

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). (English)

1 reference

4 August 2017

V Guerini

1 reference

4 August 2017

V Barbui

1 reference

4 August 2017

O Spinelli

1 reference

4 August 2017

A Salvi

1 reference

4 August 2017

C Dellacasa

1 reference

4 August 2017

A Carobbio

1 reference

4 August 2017

M Introna

1 reference

4 August 2017

T Barbui

1 reference

4 August 2017

J Golay

1 reference

4 August 2017

A Rambaldi

1 reference

4 August 2017

language of work or name

1 reference

13 December 2007

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

740-747

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Jak2: normal function and role in hematopoietic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Imatinib effect on growth and signal transduction in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Histone deacetylase inhibitors: multifunctional anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Flow cytometric analysis of live cell proliferation and phenotype in populations with low viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

The use of bioinformatics to identify the genomic structure of the gene that encodes neutrophil antigen NB1, CD177

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

STAT signaling in the pathogenesis and treatment of leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

SHP-2 Regulates SOCS-1-mediated Janus Kinase-2 Ubiquitination/Degradation Downstream of the Prolactin Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Activated Jak2 with the V617F point mutation promotes G1/S phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

Hsp90 Recognizes a Common Surface on Client Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

On the molecular origins of the chronic myeloproliferative disorders: it all makes sense

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

Histone deacetylase inhibitors: biology and mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

Chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405049

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2405049

1 reference

Dimensions Publication ID

4 August 2017

1014001153

0 references

1 reference